Pramlintide for the treatment of diabetes mellitusKLEPPINGER, Erika L; VIVIAN, Eva M.The Annals of pharmacotherapy. 2003, Vol 37, Num 7-8, pp 1082-1089, issn 1060-0280, 8 p.Article

Amylin activates distributed CNS nuclei to control energy balanceMIETLICKI-BAASE, Elizabeth G; HAYES, Matthew R.Physiology & behavior. 2014, Vol 136, pp 39-46, issn 0031-9384, 8 p.Conference Paper

The Role of Pramlintide for Weight LossDUNICAN, Kaelen C; ADAMS, Nicole M; DESILETS, Alicia R et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 3, pp 538-545, issn 1060-0280, 8 p.Article

Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing studyMAGGS, David G; FINEMAN, Mark; KORNSTEIN, Jonathan et al.Diabetes/metabolism research and reviews (Print). 2004, Vol 20, Num 1, pp 55-60, issn 1520-7552, 6 p.Article

Pramlintide in the treatment of type 1 and type 2 diabetes mellitusRYAN, Gina J; JOBE, Lynetta J; MARTIN, Rhonda et al.Clinical therapeutics. 2005, Vol 27, Num 10, pp 1500-1512, issn 0149-2918, 13 p.Article

Consensus development conference on pramlintide in the management of type 1 and type 2 diabetesHIRSCH, Irl B; BLONDE, Lawrence; BUSE, John et al.Diabetes (New York, NY). 2006, Vol JUN, pp 1-13, issn 0012-1797, 13 p., HSArticle

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)HILES, Richard A; BAWDON, Roger E; PETRELLA, Ezio M et al.Human & experimental toxicology. 2003, Vol 22, Num 12, pp 623-628, issn 0960-3271, 6 p.Article

Pramlintide contre le diabète = Pramlintide and diabeteThe Medical letter on drugs and therapeutics (Edition française). 2005, Vol 27, Num 13, pp 67-69, issn 0253-8512, 3 p.Article

Pramlintide in the treatment of diabetesEDELMAN, S. V; DARSOW, T; FRIAS, J. P et al.International journal of clinical practice (Esher). 2006, Vol 60, Num 12, pp 1647-1653, issn 1368-5031, 7 p.Article

Adjunctive therapy with pramlintide in patients with type 1 or type 2 diabetes mellitusNOGID, Anna; PHAM, David Q.Pharmacotherapy. 2006, Vol 26, Num 11, pp 1626-1640, issn 0277-0008, 15 p.Article

Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetesCERIELLO, Antonio; LUSH, Cameron W; DARSOW, Tamara et al.Diabetes/metabolism research and reviews (Print). 2008, Vol 24, Num 2, pp 103-108, issn 1520-7552, 6 p.Article

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targetsRATNER, R; WHITEHOUSE, F; FINEMAN, M. S et al.Experimental and clinical endocrinology & diabetes. 2005, Vol 113, Num 4, pp 199-204, issn 0947-7349, 6 p.Article

The Role of Prandial Pramlintide in the Treatment of Adolescents With Type 1 DiabetesRODRIGUEZ, Luisa M; MASON, Kimberly J; HAYMOND, Morey W et al.Pediatric research. 2007, Vol 62, Num 6, pp 746-749, issn 0031-3998, 4 p.Article

Isolation and identification of peptide degradation products of heat stressed pramlintide injection drug productHEKMAN, C; DEMOND, W; DIXIT, T et al.Pharmaceutical research. 1998, Vol 15, Num 4, pp 650-659, issn 0724-8741Article

Clinical Experience With the Addition of Pramlintide in Patients With Insulin-Requiring Type 2 DiabetesELKIND-HIRSCH, Karen; BUTLER, William J; BHUSHAN, Madhu et al.Diabetes care. 2008, Vol 31, Num 1, pp 39-40, issn 0149-5992, 2 p.Article

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects : a 6-wk translational research studySMITH, Steven R; BLUNDELL, John E; BUMS, Colleen et al.American journal of physiology. Endocrinology and metabolism. 2007, Vol 56, Num 2, issn 0193-1849, E620-E626Article

Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in type 1 diabetic subjectsØRSKOV, L; NYHOLM, B; HOVE, K. Y et al.Diabetic medicine. 1999, Vol 16, Num 10, pp 867-874, issn 0742-3071Article

Pramlintide for the treatment of insulin-requiring diabetes mellitus: Rationale and review of clinical dataKRUGER, Davida F; GLOSTER, Maurice A.Drugs (Basel). 2004, Vol 64, Num 13, pp 1419-1432, issn 0012-6667, 14 p.Article

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with Type 1 diabetesMARRERO, David G; CREAN, John; BEI ZHANG et al.Diabetes care. 2007, Vol 30, Num 2, pp 210-216, issn 0149-5992, 7 p.Article

A Pilot Trial of Pramlintide Home Usage in Adolescents With Type 1 DiabetesKISHIYAMA, Christopher M; BURDICK, Patricia L; COBRY, Erin C et al.Pediatrics (Evanston). 2009, Vol 124, Num 5, pp 1344-1347, issn 0031-4005, 4 p.Article

Amylin Receptor Signaling in the Ventral Tegmental Area is Physiologically Relevant for the Control of Food IntakeMIETLICKI-BAASE, Elizabeth G; RUPPRECHT, Laura E; OLIVOS, Diana R et al.Neuropsychopharmacology (New York, NY). 2013, Vol 38, Num 9, pp 1685-1697, issn 0893-133X, 13 p.Article

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetesWHITEHOUSE, Fred; KRUGER, Davida F; FINEMAN, Mark et al.Diabetes care. 2002, Vol 25, Num 4, pp 724-730, issn 0149-5992Article

A Biophysical Characterization of the Peptide Drug Pramlintide (AC137) Using Empirical Phase DiagramsNONOYAMA, Akihisa; LAURENCE, Jennifer S; GARRIQUES, Liza et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 7, pp 2552-2567, issn 0022-3549, 16 p.Article

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetesCHAPMAN, I; PARKER, B; HOROWITZ, M et al.Diabetologia (Berlin). 2005, Vol 48, Num 5, pp 838-848, issn 0012-186X, 11 p.Article

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulinTHOMPSON, R. G; PEARSON, L; SCHOENFELD, S. L et al.Diabetes care. 1998, Vol 21, Num 6, pp 987-993, issn 0149-5992Article